Modification of myocardial infarction size after coronary occlusion.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D003326:Coronary Circulation / Q000187:drug effects; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004285:Dogs; D004554:Electric Countershock; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D004071:Digitalis Glycosides; D006821:Hyaluronoglucosaminidase